BioSpace: Movers and Shakers, Aug. 9 By Alex Keown
Altasciences – Beatrice Setnik was named CSO of Quebec-based Altasciences. She has held roles with Ventana Clinical Research in Canada, King Pharmaceuticals and Pfizer in North Carolina, and since 2014 with Syneos Health (formerly INC Research).
Altasciences Welcomes Dr. Beatrice Setnik as Chief Scientific Officer
Laval, Quebec, August 7, 2019 – Altasciences is pleased to welcome Dr. Beatrice Setnik, Ph.D. to the role of Chief Scientific Officer, supporting our internal and external clients with her expertise in all areas relating to early drug development.
Beatrice has a Ph.D. in Pharmacology and Neuroscience from the University of Toronto and since 2005 has been involved in clinical trials in Canada and the U.S.A.; with Ventana Clinical Research in Canada, King Pharmaceuticals and Pfizer in North Carolina, and since 2014 with Syneos Health (formerly INC Research). She has extensive experience in the design, conduct, and reporting of trials in a wide range of therapeutic areas, including expertise in the assessment of abuse and dependence potential of CNS-active drugs. In addition, she is an Adjunct Professor in the Department of Pharmacology and Toxicology at the University of Toronto and regularly participates in FDA meetings and workshops.
Beatrice’s wealth of knowledge and experience will ensure high-level scientific guidance and input on study designs, protocols, and medical and scientific feasibility for new inquiries for current and prospective clients.
“We are extremely fortunate to add a candidate of such caliber and talent to our team. We look forward to Dr. Setnik’s contributions which will reinforce Altasciences’ extensive offerings in early phase preclinical and clinical research,” said Chris Perkin, CEO at Altasciences.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com
ISSUE NO. 9 — Cardiac Safety Assessment in Clinical Trials
Electrocardiography (ECG) is an integral part of the new drug regulatory environment.
Mandated by regulatory bodies the world over, the thorough and precise evaluation of a new drug’s cardiac effects is
Preclinical Case Study - Assessing the Safety of Novel Therapeutics for Pediatric Indications
June 2019
Pharma Tech Outlook Top 10 CROs
Gut Health Connections to Overall Health - Part 2 of a 2-part series
Gut Health Connections to Overall Health (part 2 of 2)
In part 1 of this series, we discussed how gut bacteria, or the microbiota, affect your health, from metabolism to mood, and contribute to a number of chronic diseases.
Applying the 3Rs by Implementing Social Housing Configuration
Quantitation of a PEGylated Human Parathyroid Hormone (1-34) Analog in Rat Plasma Using a Hybrid Immunoaffinity Bottom-Up LC-MS/MS Assay
The Application of Light-Absorbing Photostabilizers for the Determination of Protoporphyrin IX in Human Plasma by LC-MS/MS